In a major stride toward tackling aggressive breast cancer, researchers from The Hebrew University of Jerusalem have developed druglike molecules that degrade a previously “undruggable” cancer-driving protein. The target, HuR—an RNA-binding protein known for stabilizing oncogenic messages—has long eluded traditional therapies. Now, using next-generation strategies involving molecular glues and PROTACs, researchers have uncovered a promising route to disarm HuR and suppress tumor growth from the inside out.
